Amyloid oligomers: A joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis
Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
Parkinson's disease: biomarkers, treatment, and risk factors
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused mainly by
lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement …
lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement …
The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells
The self-assembly of α-synuclein (αS) into intraneuronal inclusion bodies is a key
characteristic of Parkinson's disease. To define the nature of the species giving rise to …
characteristic of Parkinson's disease. To define the nature of the species giving rise to …
Marine natural products
Covering: January to December 2017 This review covers the literature published in 2017 for
marine natural products (MNPs), with 740 citations (723 for the period January to December …
marine natural products (MNPs), with 740 citations (723 for the period January to December …
The role of α-synuclein oligomers in Parkinson's disease
X Du, X **e, R Liu - International journal of molecular sciences, 2020 - mdpi.com
α-synuclein (α-syn) is a protein associated with the pathogenesis of Parkinson's disease
(PD), the second most common neurodegeneration disease with no effective treatment …
(PD), the second most common neurodegeneration disease with no effective treatment …
Initiation and propagation of α-synuclein aggregation in the nervous system
The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons
in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of …
in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of …
Disease modification in Parkinson's disease: current approaches, challenges, and future considerations
The greatest unmet therapeutic need in Parkinson's disease is the development of treatment
that slows the relentless progression of the neurodegenerative process. The concept of …
that slows the relentless progression of the neurodegenerative process. The concept of …
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance
The classic view portrays Parkinson disease (PD) as a motor disorder resulting from loss of
substantia nigra pars compacta dopaminergic neurons. Multiple studies, however, describe …
substantia nigra pars compacta dopaminergic neurons. Multiple studies, however, describe …
Emerging therapies in Parkinson disease—repurposed drugs and new approaches
Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …
replacement and provision of symptomatic relief. Current treatments cause undesirable …
Polyamines in Parkinson's disease: balancing between neurotoxicity and neuroprotection
The polyamines putrescine, spermidine, and spermine are abundant polycations of vital
importance in mammalian cells. Their cellular levels are tightly regulated by degradation …
importance in mammalian cells. Their cellular levels are tightly regulated by degradation …